Oxford Gene Technology (OGT), a provider of clinical genetics and diagnostic solutions to advance medicine, has announced a project with the University of Virginia Center for Public Health Genomics.
In the study, Prof Stephen Rich, director of the centre, will utilise OGT's Genefficiency aCGH microarray screening service to investigate the relationship between genome structural variation and susceptibility to type 1 (T1) diabetes.
Employing an array design developed from recent work exploring genome wide copy number variations (CNVs), the study will utilise an extensive collection of more than 10,000 patient samples in the hope of identifying CNVs associated with T1 diabetes.
This will allow researchers to better predict disease susceptibility and highlight potential opportunities for therapeutic manipulation.
T1 diabetes results from the misregulation of blood sugar levels.
Studies investigating the presence of single nucleotide polymorphisms (SNPs) have indentified more than 50 areas of the human genome associated with diabetes, although the data gathered so far fails to fully explain the inherited component of the disease.
In a number of diseases, including autism and Crohn's disease, genomic variations affecting disease phenotypes have been associated with CNVs rather than SNPs, prompting this investigation by Prof Rich into the effect of CNVs on the incidence of T1 diabetes.
'We decided to utilise OGT's Genefficiency service to generate data from our samples following their very successful screening of 22,000 samples in 20 weeks for the Wellcome Trust Case Control Consortium CNV study,' said Rich.
The study, funded by the National Institute of Diabetes, Digestive and Kidney Diseases, commences with a 1,000 patient pilot study, followed by the wide-scale characterisation of more than 10,000 samples from affected sibling pair families, trios and case-control samples.
This will allow the precise, genome-wide characterisation of markers associated with T1 diabetes.
